To amend certain provisions in the Federal Food, Drug, and Cosmetic Act relating to the discontinuance or interruption in the production of life-saving drugs so as to apply such provisions with respect to life-saving devices, and for other purposes.

2/9/2022, 1:42 AM

Congressional Summary of HR 6062

This bill expands existing requirements relating to supply shortages of life-saving drugs to also apply to life-saving medical devices.

Generally, a manufacturer must (1) notify the Food and Drug Administration (FDA) of supply interruptions in certain circumstances, (2) provide for the expedited review of a new device that may mitigate the shortage, and (3) allow the FDA to authorize the importation of the device for emergency medical care.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill HR 6062

Bill HR 6062 is currently in the status of Bill Introduced since March 3, 2020. Bill HR 6062 was introduced during Congress 116 and was introduced to the House on March 3, 2020. Bill HR 6062's most recent activity was Sponsor introductory remarks on measure. (CR H1476) as of March 4, 2020

Bipartisan Support of Bill HR 6062

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill HR 6062

Primary Policy Focus

Health

Potential Impact Areas

- Drug safety, medical device, and laboratory regulation

- Health technology, devices, supplies

Alternate Title(s) of Bill HR 6062

To amend certain provisions in the Federal Food, Drug, and Cosmetic Act relating to the discontinuance or interruption in the production of life-saving drugs so as to apply such provisions with respect to life-saving devices, and for other purposes.